Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI-2: DTG + 3TC vs DTG + TDF/FTC in HIV-1
NCT02831764Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus type 1 infection (HIV-1) comparing DTG + 3TC with DTG + TDF/FTC (2 arms). Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL at Week 48. Started Jul 2016; status: completed.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02831764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02831764.